ARQT Stock Analysis: Buy, Sell, or Hold?
ARQT - Arcutis Biotherapeutics, Inc. Common Stock
$23.63
-0.47 (-1.95%)
▼
5d:
+5.59%
30d:
-2.03%
90d:
-18.63%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 05, 2026
29d
Get Alerted When ARQT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ARQT trading at deep discount. Market pricing in -27.2% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ARQT trading at deep discount. Market pricing in -27.2% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$62.25
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$38.65
38.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ARQT is currently trading at $23.63, which is considered fair relative to its 30-day fair value range of $22.03 to $25.75. From a valuation perspective, the stock is trading at a discount (Forward PE: 18.5) compared to its historical average (47.9). Remarkably, the market is currently pricing in an annual earnings decline of 27.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ARQT is in a strong uptrend. Immediate support is located at $21.12, while resistance sits at $24.52.
Market Sentiment: ARQT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.75 (+47.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ARQT is in a strong uptrend. Immediate support is located at $21.12, while resistance sits at $24.52.
Market Sentiment: ARQT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.75 (+47.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$22.03 -
$25.75
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 47.1% below Wall St target ($34.75)
Fair Price Analysis
30-Day Fair Range
$22.03 -
$25.75
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$21.12
Resistance Level
$24.52
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.48
Wall Street Target
$34.75
(+47.1%)
Revenue Growth (YoY)
81.5%
Profit Margin
-4.3%
Valuation Discount vs History
-27.2% cheaper
PE vs Historical
18.5 vs 47.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-27.2%
(market-implied from PE analysis)
1-Year Target
$21.27
(-10%)
2-Year Target
$19.14
(-19%)
3-Year Target
$17.23
(-27%)
3-Yr Target (if PE normalizes)
(PE: 18→48)
$44.65
(+89%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: 248.3%)
$88.77
(+276%)
Base:
(SPY PE: 18.5, Growth: 248.3%)
$79.75
(+238%)
Bear:
(PE: 15.7, Growth: 248.3%)
$67.79
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.5 to 47.9
Stabilization Target:
$61.24
(+159.2%)
PE Expansion Potential:
+159.2%
Share & Embed Analysis
Last updated: April 05, 2026 8:53 AM ET
Data refreshes hourly during market hours. Next update: 9:53 AM
Data refreshes hourly during market hours. Next update: 9:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARQT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Latha Vairavan
SELL
2853 shares
2026-03-02
Masaru Matsuda
SELL
8733 shares
2026-03-02
Patrick Burnett
SELL
6287 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 65 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
